CAR-T cells targeting activated hepatic stellate cells ameliorate liver fibrosis in mouse models - PubMed
12 hours ago
- #CAR-T therapy
- #Liver fibrosis
- #Hepatocellular carcinoma
- CAR-T cells targeting activated hepatic stellate cells (HSCs) show promise in treating liver fibrosis.
- The study focused on CAR-T cells engineered to target fibroblast activation protein (FAP), overexpressed on activated HSCs.
- FAP CAR-T therapy significantly reduced liver fibrosis in multiple mouse models (p <0.0001).
- The therapy specifically eliminated activated HSCs and increased hepatic T cell infiltration.
- FAP CAR-T cells outperformed a FAP inhibitor in antifibrotic efficacy (p <0.001).
- The treatment also effectively prevented the progression of hepatocellular carcinoma (HCC) (p <0.01).
- This approach offers a novel therapeutic strategy for liver fibrosis and HCC, though further safety and efficacy studies are needed.